VREX Stock Analysis: Buy, Sell, or Hold?
VREX - Varex Imaging Corporation Common Stock
$10.50
-0.12 (-1.13%)
▼
5d:
-2.6%
30d:
-19.29%
90d:
-9.87%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When VREX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: VREX appears deeply undervalued. Market expects -9.0% annual earnings decline despite 453% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: VREX appears deeply undervalued. Market expects -9.0% annual earnings decline despite 453% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$22.36
Based on 10.1% avg growth
INTRINSIC VALUE TODAY
$13.88
24.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VREX is currently trading at $10.50, which is considered slightly low relative to its 30-day fair value range of $10.46 to $12.52. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.0) compared to its historical average (13.2). Remarkably, the market is currently pricing in an annual earnings decline of 9.0% over the next few years. This pessimistic expectation contrasts with the company's recent 453.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, VREX is showing sideways momentum. The price is currently testing key support at $10.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $18.40 (+75.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VREX is showing sideways momentum. The price is currently testing key support at $10.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $18.40 (+75.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$10.46 -
$12.52
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 75.2% below Wall St target ($18.40)
Fair Price Analysis
30-Day Fair Range
$10.46 -
$12.52
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$1.09
(10.4%)
Support & Resistance Levels
Support Level
$10.27
Resistance Level
$11.23
Current Trend
Sideways
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.97
Wall Street Target
$18.40
(+75.2%)
Revenue Growth (YoY)
4.9%
Earnings Growth (YoY)
453.4%
Profit Margin
-7.9%
Valuation Discount vs History
-9.0% cheaper
PE vs Historical
10.0 vs 13.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.0%
(market-implied from PE analysis)
1-Year Target
$9.56
(-9%)
2-Year Target
$8.70
(-17%)
3-Year Target
$7.91
(-25%)
3-Yr Target (if PE normalizes)
(PE: 10→13)
$10.48
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 16.1%)
$33.88
(+223%)
Base:
(SPY PE: 10.0, Growth: 16.1%)
$16.42
(+56%)
Bear:
(PE: 8.5, Growth: 16.1%)
$13.95
(+33%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.0 to 13.2
Stabilization Target:
$13.90
(+32.4%)
PE Expansion Potential:
+32.4%
Share & Embed Analysis
Last updated: April 05, 2026 5:01 PM ET
Data refreshes hourly during market hours. Next update: 6:01 PM
Data refreshes hourly during market hours. Next update: 6:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VREX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 61 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 62 BUY |
